The Future of Hemp-Derived Delta-9 THC Headlines CBT’s Most-Read Articles for March

The future of hemp-derived delta-8 and -9 THC products remains unclear leading up to this year’s anticipated reauthorization of the 2018 Farm Bill, as a patchwork of state regulations have gone unaddressed at the federal level.

But as products containing these intoxicating hemp derivatives have taken off in consumer popularity and business profitability in recent years, the fate of this marketplace continues to attract the attention of regulators, stakeholders and our readers at Cannabis Business Times.

Leading our monthly list of top 10 articles in March was a contributed piece by a quartet of attorneys at Goodwin Procter LLP, who provided a thorough examination of the widespread availability for hemp-derived delta-9 products, federal and state regulations, and what could be next for U.S. hemp cultivators and processors counting on this cannabinoid.

On a similar topic, an article by CBT Editorial Director Noelle Skodzinski about hemp-related products sold on Amazon that violate federal regulations, according to a report by CBD Oracle, took the No. 2 spot in this month’s most-read articles.

Among other articles readers engaged with most included those on a potential cannabis rescheduling roadblock with the U.S. Drug Enforcement Administration’s five-factor test; federal lawmakers challenging forthcoming tribal cannabis sales in North Carolina; and Trulieve’s $113 million refund for 280E taxes paid.

Catch up on all the top 10 most-read articles below: